Methods of protecting against neurodegeneration
AssigneesBioVentures, LLC, The United States AS Represented By the Department of Veterans Affairs
InventorsRobert Shmookler Reis, Peter Crooks, Srinivas Ayyadevara
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).
Claims7
A method to reduce protein aggregates in the central nervous system of a subject, the method comprising administering to the subject a composition comprising a compound that binds glial fibrillary acidic protein (GFAP), wherein the compound is a compound of Formula (I):
- wherein
- R1, R2, R3, R4, and R5 are hydrogen;
- R7, R8, R9, R10, and R11 are independently selected from hydrogen or alkoxy;
- R6 is CN;
- X is C or S;
- Y is N, S, or NH;
- independently are a single bond that is present or absent, with the proviso that both are not present at the same time;
- and
- wherein the protein aggregates contain or are initiated by Aβ1-42, β-amyloid, α-synuclein, and/or a polyglutamine array expansion protein.
A method to reduce protein aggregates in the central nervous system of a subject, the method comprising administering to the subject a composition comprising a compound that binds glial fibrillary acidic protein (GFAP), wherein the compound is
- wherein the protein aggregates contain or are initiated by Aβ1-42, β-amyloid, α-synuclein, and/or a polyglutamine array expansion protein.
A method to reduce protein aggregates in the central nervous system of a subject, the method comprising administering to the subject a composition comprising a compound that binds glial fibrillary acidic protein (GFAP), wherein the compound is a compound of Formula (I):
- wherein
- R1, R2, R3, R4, and R5 are hydrogen;
- R7, R8, R9, R10, and R11 are independently selected from hydrogen or alkoxy;
- R6 is CN;
- X is C;
- Y is N, S, or NH;
- independently are a single bond that is present or absent, with the proviso that both are not present at the same time;
- and
- wherein the protein aggregates contain or are initiated by Aβ1-42, β-amyloid, α-synuclein, and/or a polyglutamine array expansion protein.
Dependencies are inferred from the claim text.